These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30857932)

  • 41. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).
    Matassov D; Cupo A; Galarza JM
    Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Functional Food Mixture "Protector" Reinforces the Protective Immune Parameters against Viral Flu Infection in Mice.
    Mansoor KA; Qadan F; Schmidt M; Qinna NA; Badr M; Matalka KZ
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29890620
    [No Abstract]   [Full Text] [Related]  

  • 45. Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.
    Kim ED; Han SJ; Byun YH; Yoon SC; Choi KS; Seong BL; Seo KY
    PLoS One; 2015; 10(9):e0137608. PubMed ID: 26355295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemical-free inactivated whole influenza virus vaccine prepared by ultrashort pulsed laser treatment.
    Tsen SW; Donthi N; La V; Hsieh WH; Li YD; Knoff J; Chen A; Wu TC; Hung CF; Achilefu S; Tsen KT
    J Biomed Opt; 2015 May; 20(5):051008. PubMed ID: 25423046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection.
    Lay M; Callejo B; Chang S; Hong DK; Lewis DB; Carroll TD; Matzinger S; Fritts L; Miller CJ; Warner JF; Liang L; Fairman J
    Vaccine; 2009 Jun; 27(29):3811-20. PubMed ID: 19406188
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of protective immunity against influenza A/Jiangxi-Donghu/346/2013 (H10N8) in mice.
    Kuah LF; Tang LH; Sutton T; Lim JH; Sin WL; Lamirande E; Subbarao K; Lau YF
    J Gen Virol; 2017 Feb; 98(2):155-165. PubMed ID: 27983474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro.
    Bodewes R; Geelhoed-Mieras MM; Heldens JG; Glover J; Lambrecht BN; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    Vaccine; 2009 Nov; 27(49):6833-9. PubMed ID: 19772942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccine-mediated protection of pigs against infection with pandemic H1N1 2009 swine influenza A virus requires a close antigenic match between the vaccine antigen and challenge virus.
    Everett HE; Aramouni M; Coward V; Ramsay A; Kelly M; Morgan S; Tchilian E; Canini L; Woolhouse MEJ; Gilbert S; Charleston B; Brown IH; Brookes SM
    Vaccine; 2019 Apr; 37(17):2288-2293. PubMed ID: 30914224
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in mice.
    Xu W; Zheng M; Zhou F; Chen Z
    Clin Vaccine Immunol; 2015 Mar; 22(3):327-35. PubMed ID: 25589552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection.
    Kim YH; Bang YJ; Park HJ; Li Ko H; Park SI; Hwang KA; Kim H; Nam JH
    Vaccine; 2020 Sep; 38(39):6141-6152. PubMed ID: 32739118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis.
    Ato M; Takahashi Y; Fujii H; Hashimoto S; Kaji T; Itamura S; Horiuchi Y; Arakawa Y; Tashiro M; Takemori T
    Vaccine; 2013 Apr; 31(17):2184-90. PubMed ID: 23434386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections.
    Tseng YC; Wu CY; Liu ML; Chen TH; Chiang WL; Yu YH; Jan JT; Lin KI; Wong CH; Ma C
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4200-4205. PubMed ID: 30782805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Immune protective effectiveness of seasonal influenza spilt vaccine against homologous and heterogonous subtypes of influenza virus in mice].
    Huang BY; Wang XP; Wang WL; Hu W; Gao Q; Tan WJ; Ruan L
    Bing Du Xue Bao; 2011 May; 27(3):265-73. PubMed ID: 21774253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.
    Jeisy-Scott V; Kim JH; Davis WG; Cao W; Katz JM; Sambhara S
    J Virol; 2012 Oct; 86(20):10988-98. PubMed ID: 22837197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of influenza vaccination of elderly rhesus macaques is dramatically improved by addition of a cationic lipid/DNA adjuvant.
    Carroll TD; Matzinger SR; Barry PA; McChesney MB; Fairman J; Miller CJ
    J Infect Dis; 2014 Jan; 209(1):24-33. PubMed ID: 24141979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(+) T cell responses.
    Fernando GJ; Zhang J; Ng HI; Haigh OL; Yukiko SR; Kendall MA
    J Control Release; 2016 Sep; 237():35-41. PubMed ID: 27381247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Increasing the immunogenicity of inactivated chitosan adjuvanted vaccine from A/California/7/09 (H1N1) strain and analyzing the antigenic specificity of this influenza virus strain].
    Gendon IuZ; Markushin SG; Vasil'ev IuM; Akopova II; Krivtsov GG
    Vopr Virusol; 2012; 57(1):28-33. PubMed ID: 22624470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.